Artiva (ARTV) SVP sells 3,095 shares in automatic tax sell-to-cover

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. senior vice president of research and development Heather Raymon reported an open-market sale of 3,095 shares of common stock at a weighted average price of $9.0078 per share. According to the company’s sell-to-cover policy, these shares were sold automatically to satisfy tax withholding on vested restricted stock units. After this transaction, Raymon directly holds 148,228 Artiva shares.

Insights

Equity compensation analyst

Routine, automatic tax-related sale with limited signaling value.

The transaction involves 3,095 Artiva Biotherapeutics shares sold at a weighted average of $9.0078 per share. A footnote states the issuer uses a sell-to-cover policy for tax withholding on vested restricted stock units.

The filing explains these shares were sold automatically to satisfy tax obligations and were not at Heather Raymon’s discretion. Following the sale, Raymon still directly owns 148,228 shares, indicating the sale affects only a small portion of the disclosed holdings.

Insider Trade Summary

Net Seller: 3,095 shares ($27,879)

Net Sell 1 txn

Insider Raymon Heather

Role SVP, Research and Development

Sold 3,095 shs ($28K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,095	$9.0078	$28K

Holdings After Transaction: Common Stock — 148,228 shares (Direct, null)

Footnotes (1)

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7447 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 3,095 shares Weighted average sale price: $9.0078 per share Price range: $8.7447–$9.0104 per share +1 more

4 metrics

Shares sold 3,095 shares Open-market sale on 2026-05-19 linked to RSU tax withholding

Weighted average sale price $9.0078 per share Average price for reported 3,095-share sale

Price range $8.7447–$9.0104 per share Range of prices for shares sold in the transaction

Shares held after transaction 148,228 shares Direct Artiva common stock ownership following the sale

Key Terms

sell-to-cover policy, restricted stock units, weighted average sale price

3 terms

sell-to-cover policy financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person."

restricted stock units financial

"tax withholding obligations in connection with the vesting and release of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7447 and $9.0104."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raymon Heather

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Research and Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		S		3,095(1)	D	$9.0078(2)	148,228	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7447 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Artiva Biotherapeutics (ARTV) report for Heather Raymon?

Artiva Biotherapeutics reported that SVP of Research and Development Heather Raymon sold 3,095 shares of common stock. The sale was tied to tax withholding on vested restricted stock units under the company’s sell-to-cover policy and was not a discretionary trade.

How many Artiva (ARTV) shares did Heather Raymon sell and at what price?

Heather Raymon sold 3,095 Artiva common shares. The weighted average sale price was $9.0078 per share, with individual sale prices ranging between $8.7447 and $9.0104, according to the Form 4 disclosure and related pricing footnote.

Why were Heather Raymon’s Artiva (ARTV) shares sold according to the Form 4?

The shares were sold to cover tax withholding obligations arising from the vesting and release of restricted stock units. Artiva has adopted a sell-to-cover policy, and the filing states the sales were automatic and not at Heather Raymon’s discretion.

How many Artiva (ARTV) shares does Heather Raymon hold after the reported sale?

After the reported transaction, Heather Raymon directly holds 148,228 shares of Artiva common stock. This post-transaction balance, shown in the Form 4, provides context for the size of the 3,095-share sale relative to her remaining holdings.

Was Heather Raymon’s Artiva (ARTV) stock sale part of a trading plan?

The Form 4 states Artiva has a sell-to-cover policy for tax withholding on restricted stock units. It describes the reported sales as automatic to satisfy tax obligations, rather than discretionary trades initiated independently by Heather Raymon.